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Introduction
The androgen receptor (AR) is a member of the steroid receptor subfamily with well known biological and therapeutic importance in prostate cancer. There is emerging evidence that the androgen signaling pathway also may play a critical role in normal and malignant breast tissue (1) . In particular, AR is expressed in normal breast epithelial cells and in approximately 70-90% of invasive breast carcinomas, a percentage equal to or higher than that of either estrogen receptor (ER) (70-80%) or progesterone receptor (PR) (50-70%) (2) . In addition, 25-82% of metastatic breast tumors that are ER-negative and PR-negative express a significant amount of AR (3) .
Previous studies have suggested that AR may be both a prognostic factor for survival and a predictive factor for response to endocrine treatment in patients with breast cancer (1, (4) (5) (6) (7) (8) (9) (10) (11) (12) . Of the studies conducted to date, most were small, with only two including more than 350 breast cancer cases. The largest study evaluating the prognostic significance of AR was conducted on 1,181 patients with primary breast cancer.
However, in this study, the only prognostic factor that was taken into account in the analysis was ER status (8) . In addition, few studies have examined the prognostic value of AR expression according to ER status (1, 2, 7, 8, 12) or in triple negative tumors (5) .
The purpose of the current study was to evaluate the associations between AR expression and survival outcomes in a large cohort of postmenopausal women with stage I to III breast cancer identified from the Nurses' Health Study (NHS), and to assess this association stratified by ER status as well as in the triple negative subtype of breast cancer.
Study population.
The NHS is a prospective cohort study established in 1976 when 121,700 female registered nurses from across the United States, aged 30-55 years, completed a mailed questionnaire on factors that influence women's health. Follow-up questionnaires have since been sent out every two years to the NHS participants to update exposure information and ascertain non-fatal incident diseases. Follow-up rate from 1976 through December 2007 is 98.9% in our study.
Incident breast cancer was ascertained by the biennial questionnaire to study participants. For any report of breast cancer, written permission was obtained from participants to review their medical records to confirm the diagnosis and to classify cancers as in situ or invasive, by histological type, size and presence or absence of metastases. Overall, 99% of self-reported breast cancers have been confirmed. To identify breast cancer cases in non-respondents who died, death certificates and medical records for all deceased participants were obtained to ascertain cause of death. This study was approved by the Human Subjects Committee at Brigham and Women's Hospital in Boston, Massachusetts.
Measurement of mortality and breast cancer recurrence
Breast cancer cases were followed from the date of diagnosis until January 1, 2008 or death, whichever came first. Ascertainment of deaths included reporting by next of kin or postal authorities or searching the National Death Index. Approximately 98% of deaths in the NHS have been identified by these methods (14) (15) (16) . Cause of death was ascertained from death certificates and physician review of medical records.
Research. We assumed that breast cancer had recurred if a woman with a primary breast cancer reported a second cancer in lung, liver, bone or brain cancer, because these are the most common sites of recurrence. We reviewed medical records to distinguish primary lung cancer from breast cancer metastases to the lung. In addition, women who died from breast cancer were assumed to have recurred 2 years prior to the date of death (17) .
Because our questionnaire interval is every 2 years, women with breast cancer frequently die before they can tell us about their recurrence. Approximately 92% of recurred cases are calculated this way due to missing information about the sites and time of recurrence.
Breast cancer tissue microarrays and immunohistochemical analysis
Collection of breast cancer tissue blocks and tissue microarray (TMA) construction have been described in detail previously (18) . Briefly, we collected archived formalinfixed paraffin-embedded breast cancer blocks from participants with incident breast cancers over 20 years of follow-up (1976 to 1996) . Of the 5,610 women with breast cancer that were eligible for block collection, we obtained pathology samples for 3, 752 participants. Hematoxylin and eosin sections from those cases were reviewed to confirm the diagnosis, classify the cancer according to histological type and grade, and circle the area from which the cores for the TMAs would be taken. TMAs were constructed in the Dana Farber Harvard Cancer Center Tissue Microarray Core Facility, Boston, Massachusetts. Three cores 0.6 mm in diameter were obtained from each breast cancer sample and inserted into the recipient TMA blocks. In total, 23 TMA blocks were constructed from 3,093 cancers and positive lymph nodes from 2,897 participants.
We performed immunohistochemical staining for AR, ER, PR, human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6 (CK5/6) and epidermal growth factor (19) .
Selection criteria for analysis
We included women with invasive breast cancer diagnosed after return of the 1976 baseline questionnaire through August, 1997, whose tumors were included in the TMAs. 
Statistical Analysis
AR-positive and AR-negative tumors were compared according to tumor characteristics and treatment variables by the chi-square test or Wilcoxon rank sum test, as appropriate. Three survival end points were evaluated in this study. In overall survival analysis, death from any cause was the end point; in breast cancer specific survival analysis, death from breast cancer was the end point and deaths from any other causes were censored; in recurrence-free interval analysis, breast cancer recurrence was the end point. Survival curves were estimated by the Kaplan-Meier method with a log-rank test to assess statistical significance. Cox proportional hazard regression models were used to evaluate the association of AR status with survival outcomes after adjusting for covariates. Because approximately 19% of women were missing information on treatment, we considered them as a separate group for our multivariate analysis. We conducted sensitivity analyses excluding women with missing treatment information. All analyses were performed using SAS version 9.1. All statistical tests were two sided and P<0.05 was considered statistically significant. 
Results

Participants and Breast Tumor Characteristics
Survival Estimates
The median length of follow-up was 14 years. Overall, there were 595 total deaths, 279 breast cancer deaths and 292 recurrences through the end of the follow-up period. Fiveand ten-year survival estimates are shown in Table 2 Figure 1) and overall survival (data not shown) were similar to breast cancer specific curves.
Multivariate Analysis
In multivariate analysis, there was no overall association between AR status and breast cancer death (hazard ratio, 0.96, 95 percent confidence interval, 0.69 to 1.34) (Table 3) .
However, the association varied markedly by ER status (P interaction =0.0019), hence, a stratified analysis was performed. Among ER-positive tumors (1,164 cases), we found that compared with AR-negative tumors, AR-positive tumors were associated with a 30% reduction in breast cancer mortality (hazard ratio, 0.68; 95 percent confidence interval, 0.47 to 0.99). Similar results were observed for overall mortality and risk of breast cancer recurrence, but not all statistically significant (Table 3) . However, we were underpowered to evaluate the association between AR status and survival outcomes according to other treatment subgroups. In addition, we also conducted an analysis limited to women with triple-negative (ER-/PR-/HER2-negative) tumors.
Among those with triple-negative breast cancer (211 cases), women with AR-positive tumors had an 83% increase in overall mortality compared with those with AR-negative tumors (multivariate hazard ratio (model 3), 1.83; 95 percent confidence interval, 1.11 to 3.01; P=0.02).
Discussion
We conducted the largest study to date examining the role of AR in breast cancer women with ER-negative breast cancer, no association between AR status and overall survival was observed (1) . Similarly, Agoff et al. also found that AR expression in ERnegative breast cancer (n=69) was not significantly associated with breast cancer survival in multivariate analyses, but this was attributed to the small sample size (7). Rakha et al.
reported that in triple-negative tumors (n=282), especially those which were lymph nodepositive, absence of AR expression was associated with higher nuclear grade and increased development of recurrence and distant metastasis (24) . Luo et al. also found that the expression of AR was associated with higher 5-year disease-free survival in 137 triple negative breast cancer cases (25) . Another study of 97 women with triple negative breast tumors found that AR levels were not a significant prognostic factor for recurrence-free interval (5) . In contrast, among women with ER-and triple negative tumors in our study, AR expression was associated with increased mortality. While there are some data to support an adverse role of AR in ER-negative breast cancer, these results could also be due to chance. Based on microarray data, a subclass of tumors termed 'molecular apocrine' have been identified that are ER-/AR+ and have increased androgen signaling (26) . Using publicly available Sorlie and van't Veer microarray data sets, Farmer et al reported that the molecular apocrine profile was associated with poor survival. There are studies in cell lines suggesting that androgens may induce proliferative effects in ER-negative cells that are dependent on AR (27) . Thus, we may be capturing this subset of molecular apocrine tumors when examining the ER-/AR+ tumors.
Taken together, there is not much consistency with respect to survival outcomes associated with AR status among ER-and triple negative cases. These differences may be attributable to small sample sizes, and differences in length of follow-up. The current study is one of the largest to evaluate the role of AR in this subset, with over 31 years of follow-up. In addition, the frequency of AR-positive cases among triple negative tumors in our study was 37% (78/211). This is similar to what has been observed in other studies, where the proportion of AR-positive tumors ranges from 28% to 43% (23, 25, 28) . Also similar to other retrospective studies, we observed that AR was significantly associated with HER2 overexpression (P=0.004) in ER-negative tumors (7, 23) . However, we also saw a significant association in ER-positive tumors, which is not consistent with the results published by Park et al. (23) . Given these differences we did include HER2 status in our multivariable models and found no differences in our survival results.
Research. 
Currently, there are no available targeted therapies for women with triple negative disease. However, there are therapeutic targets of AR. Given that the triple negative subtype has the worst overall and disease free survival compared with other breast cancer subtypes (13) , and more than one third of triple negative breast cancers are AR-positive, this represents a potential opportunity for novel targeted treatment for these women.
Bicalutamide is a nonsteroidal antiandrogen therapy used to treat metastatic prostate cancer. A phase II trial of bicalutamide is currently enrolling women with ER-/PR-/AR+ breast cancers (ClinicalTrials.gov Identifier NCT00468715). Although there are no published studies of AR targeted therapy and breast cancer survival, taken together these data suggest that AR status may have a clinically important role in terms of prognosis and treatment for women with triple negative breast cancer.
Our study has a number of strengths including the large study size, long follow-up time, standardized uniform staining and scoring of molecular markers, and the prospectively collected information about lifestyle and prognostic factors. We found that other than AR status, disease grade and stage were the only other independent prognostic factors for breast cancer specific survival. Additional adjustment for treatment methods (radiation, chemotherapy and hormonal treatment), PR status, and personal characteristics (smoking status, BMI and physical activity) did not affect the results.
The current study was limited to women for whom we were able to obtain a breast cancer tissue specimen. The women from whom we were able to obtain tissue specimens were very similar with respect to demographics and tumor characteristics to those for whom we were unable to obtain tissue (18) . The pathologist scoring the TMA slides was blind to the survival outcomes of the participants. Thus, any misclassification of AR status is likely to be no differential with respect to survival outcomes and would likely bias the results towards the null.
A potential limitation of the current study is that we did not have detailed information on treatment. Treatment information was abstracted from medical records and from selfreport on questionnaires. It is possible that there could be residual confounding by treatment. However, because AR status is not routinely assessed in clinical practice it is unlikely that differences in treatment would be associated with AR status. Because hormone receptor expression is known to vary by menopausal status (28) and the majority of cases in the Nurses' Health Study are postmenopausal, we have focused the current analyses on this group.
In conclusion, we found that the association of AR status and breast cancer survival is dependent on ER expression. Among women with ER-positive tumors, AR expression was associated with significantly improved survival. Thus, immunohistochemical determination of AR status may provide additional information on prognosis in breast cancers.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. Kaplan-Meier analysis of the probability of breast cancer specific survival in postmenopausal women with stage I to III breast cancer by androgen and estrogen receptor status, Nurses' Health Study . Th P l l l t d ith f th l k t t The P value was calculated with use of the log-rank test.
